Crown Reserve Acquisition Corp. I - Warrant (CRACW)

On our desk, evaluating the CRACW warrant involves looking closely at the binary nature of the Carvix merger. While the extension of the deadline to February 2027 gives the SPAC more breathing room, the heavy conditions—like the $80M PIPE, $20M equity line, and $10M cash floor—create steep hurdles. At $0.06, the market is pricing in substantial execution risk, but the underlying trust account of over $174M provides a solid asset backstop if terms can be successfully navigated.

From a quantitative analysis perspective, modeling the 50 million earnout shares over four years alongside the core transaction requires careful scenario planning. The valuation interplay between the $1.0B reverse takeover structure and post-redemption cash floors means that any prospective investor or analyst must map out the dilution impact precisely. Watch the integration milestones closely as the definitive agreement advances toward the 2027 completion window.

Looking at the Q1 2026 filings, the net loss of $263,493 driven largely by $1.6M in warrant liability fair value adjustments highlights the inherent volatility of these derivative instruments. With 27 funds holding $1.12M in the warrants and mixed positioning—7 new openings against a handful of reductions and exits—institutional interest remains localized. Going concern doubts noted by management underline that failure to complete the combination before the extended deadline remains a critical risk factor for warrant holders.